A Global Prospective Observational Registry of Patients With Pompe Disease

NCT06121011 · clinicaltrials.gov ↗

RECRUITING

Status

500

Enrollment

INDUSTRY

Sponsor class

Conditions

Pompe Disease

Interventions

BIOLOGICAL: Cipaglucosidase alfa
DRUG: Miglustat
BIOLOGICAL: Alglucosidase alfa or Avalglucosidase alfa
OTHER: Untreated

Sponsor

Amicus Therapeutics